Adverum Biotechnologies I...

NASDAQ: ADVM · Real-Time Price · USD
3.46
0.13 (3.90%)
At close: May 02, 2025, 3:59 PM
3.40
-1.73%
After-hours: May 02, 2025, 05:21 PM EDT

Company Description

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases.

Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema.

Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek.

The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016.

Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc. logo
Country United States
IPO Date Jul 31, 2014
Industry Biotechnology
Sector Healthcare
Employees 155
CEO Dr. Laurent Fischer

Contact Details

Address:
800 Saginaw Drive
Redwood City, California
United States
Website https://www.adverum.com

Stock Details

Ticker Symbol ADVM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001501756
CUSIP Number 00773U108
ISIN Number US00773U1088
Employer ID 20-5258327
SIC Code 2836

Key Executives

Name Position
Dr. Laurent Fischer President, Chief Executive Officer & Director
Dena House Chief People Officer
Dr. R. Andrew Ramelmeier Ph.D. Chief Technology Officer
Kishor Peter Soparkar J.D. Chief Operating Officer
Linda M. Rubinstein M.A. Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer
Aneta Ferguson General Counsel
Carla Fiankan Senior Vice President of Regulatory Affairs
Dr. Romuald Corbau Ph.D. Chief Scientific Officer
Dr. Setareh Seyedkazemi Pharm.D. Chief Development Officer
Michael Steel Senior Vice President of Quality

Latest SEC Filings

Date Type Title
Apr 28, 2025 ARS Filing
Apr 28, 2025 DEFA14A Filing
Apr 28, 2025 DEF 14A Filing
Apr 28, 2025 4/A [Amend] Filing
Apr 28, 2025 4 Filing
Apr 24, 2025 4 Filing
Apr 18, 2025 PRE 14A Filing
Apr 15, 2025 8-K Current Report
Apr 15, 2025 10-K Annual Report
Apr 02, 2025 4 Filing